Skip to main content
Fig. 1 | Immunity & Ageing

Fig. 1

From: Health characteristics associated with persistence of SARS-CoV-2 antibody responses after repeated vaccinations in older persons over time: the Doetinchem cohort study

Fig. 1

A) Vaccination scheme of study persons and antibody measurements over time including 1 month after the second primary vaccination (P2) with either BNT162b2 or AZD1222, prior to the first mRNA booster vaccine and 1 month thereafter (Pre-B and B1) as the third vaccine, 1 month after the second mRNA booster vaccine, either the mRNA BNT162b2 or mRNA-1273, (2B1) as the fourth vaccine, prior to the bivalent mRNA booster vaccine (Pre-BV) (Wuhan/Omicron BA1) as the fifth vaccine and 1, 6, and 12 months thereafter (BV1, BV6, and BV12). B) Flowchart of the study cohort over time. Samples received within the defined time windows of the various timepoints post vaccination are shown. Further distinctions in sample sizes are shown between infection naïve (green block) and previously infected persons (red block) as well as booster vaccination types per timepoint

Back to article page

Immunity & Ageing

ISSN: 1742-4933

Contact us